Plain-English translation of NCT05018858 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach to treating lupus using cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs). You would receive a single intravenous infusion of 100 million of these cells, which are grown from umbilical cord tissue donated by healthy adults. The treatment is designed to help calm your immune system and reduce lupus symptoms.
Early research suggests that stem cell treatment may be safe and helpful for people with lupus, a disease where the immune system mistakenly attacks the body's own tissues. This trial aims to confirm that the medication is safe and to see how well it works for patients.
You likely qualify if…
You likely don't qualify if…
You would receive a single intravenous infusion of the stem cell treatment at the study site. After that, you would return for follow-up appointments at 1 month, 6 months, 12 months, 24 months, 36 months, and 48 months to have your blood tested and your symptoms monitored. The entire study lasts about 4 years from your initial treatment.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Antigua and Barbuda
Greece
Phase
Safety & dosing
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment target
~15 participants
Started
December 2025
Primary completion
October 2028
Last updated on clinicaltrials.gov in April 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.